Top

BMC Complementary Medicine and Therapies

Published in:

Open Access 01-12-2006 | Research article

Induction of cell cycle changes and modulation of apoptogenic/anti-apoptotic and extracellular signaling regulatory protein expression by water extracts of I'm-Yunity™ (PSP)

Authors: Tze-chen Hsieh, Peili Wu, Spencer Park, Joseph M Wu

Published in: BMC Complementary Medicine and Therapies | Issue 1/2006

Abstract

Background

I'm-Yunity™ (PSP) is a mushroom extract derived from deep-layer cultivated mycelia of the patented Cov-1 strain of Coriolus versicolor (CV), which contains as its main bioactive ingredient a family of polysaccharo-peptide with heterogeneous charge properties and molecular sizes. I'm-Yunity™ (PSP) is used as a dietary supplement by cancer patients and by individuals diagnosed with various chronic diseases. Laboratory studies have shown that I'm-Yunity™ (PSP) enhances immune functions and also modulates cellular responses to external challenges. Recently, I'm-Yunity™ (PSP) was also reported to exert potent anti-tumorigenic effects, evident by suppression of cell proliferation and induction of apoptosis in malignant cells. We investigate the mechanisms by which I'm-Yunity™ (PSP) elicits these effects.

Methods

Human leukemia HL-60 and U-937 cells were incubated with increasing doses of aqueous extracts of I'm-Yunity™ (PSP). Control and treated cells were harvested at various times and analyzed for changes in: (1) cell proliferation and viability, (2) cell cycle phase transition, (3) induction of apoptosis, (4) expression of cell cycle, apoptogenic/anti-apoptotic, and extracellular regulatory proteins.

Results

Aqueous extracts of I'm-Yunity™ (PSP) inhibited cell proliferation and induced apoptosis in HL-60 and U-937 cells, accompanied by a cell type-dependent disruption of the G₁/S and G₂/M phases of cell cycle progression. A more pronounced growth suppression was observed in treated HL-60 cells, which was correlated with time- and dose-dependent down regulation of the retinoblastoma protein Rb, diminution in the expression of anti-apoptotic proteins bcl-2 and survivin, increase in apoptogenic proteins bax and cytochrome c, and cleavage of poly(ADP-ribose) polymerase (PARP) from its native 112-kDa form to the 89-kDa truncated product. Moreover, I'm-Yunity™ (PSP)-treated HL-60 cells also showed a substantial decrease in p65 and to a lesser degree p50 forms of transcription factor NF-κB, which was accompanied by a reduction in the expression of cyclooxygenase 2 (COX2). I'm-Yunity™ (PSP) also elicited an increase in STAT1 (signal transducer and activator of transcription) and correspondingly, decrease in the expression of activated form of ERK (extracellular signal-regulated kinase).

Conclusion

Aqueous extracts of I'm-Yunity™ (PSP) induces cell cycle arrest and alterations in the expression of apoptogenic/anti-apoptotic and extracellular signaling regulatory proteins in human leukemia cells, the net result being suppression of proliferation and increase in apoptosis. These findings may contribute to the reported clinical and overall health effects of I'm-Yunity™ (PSP).

Available only for authorised users

Yang MM, Chen Z, Kwok JS: The anti-tumor effect of a small polypeptide from Coriolus versicolor (SPCV). Am J Chin Med. 1992, 20: 221-232.PubMed

Wasser SP, Weis AL: Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective. Crit Rev Immunol. 1999, 19: 65-96.PubMed

Borchers AT, Stern JS, Hackman RM, Keen CL, Gershwin ME: Mushrooms, tumors, and immunity. Proc Soc Exp Biol Med. 1999, 221: 281-293.PubMed

Kidd PM: The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev. 2000, 5: 4-27.PubMed

Hsieh TC, Wu JM: Cell growth and gene modulatory activities of Yunzhi (Windsor Wunxi) from mushroom Trametes versicolor in androgen-dependent and androgen-insensitive human prostate cancer cells. Int J Oncol. 2001, 18: 81-88.PubMed

Chu KK, Ho SS, Chow AH: Coriolus versicolor: a medicinal mushroom with promising immunotherapeutic values. J Clin Pharmacol. 2002, 42: 976-984.PubMed

Chang R: Bioactive polysaccharides from traditional Chinese medicine herbs as anticancer adjuvants. J Altern Complement Med. 2002, 8: 559-565.PubMed

Chang R, White JD: Asian therapies for cancer – coming of age. J Altern Complement Med. 2002, 8: 541-543.PubMed

Zaidman BZ, Yassin M, Mahajna J, Wasser SP: Medicinal mushroom modulators of molecular targets as cancer therapeutics. Appl Microbiol Biotechnol. 2005, 67: 453-468.PubMed

10.

Fullerton SA, Samadi AA, Tortorelis DG, Choudhury MS, Mallouh C, Tazaki H, Konno S: Induction of apoptosis in human prostatic cancer cells with beta-glucan (Maitake mushroom polysaccharide). Mol Urol. 2000, 4: 7-13.PubMed

11.

Ohno N, Miura NN, Nakajima M, Yadomae T: Antitumor 1,3-beta-glucan from cultured fruit body of Sparassis crispa. Biol Pharm Bull. 2000, 23: 866-872.PubMed

12.

Harada T, Miura N, Adachi Y, Nakajima M, Yadomae T, Ohn N: Effect of SCG, 1,3-beta-D-glucan from Sparassis crispa on the hematopoietic response in cyclophosphamide induced leukopenic mice. Biol Pharm Bull. 2002, 25: 931-939.PubMed

13.

Zhang M, Cheung PC, Zhang L: Evaluation of mushroom dietary fiber (nonstarch polysaccharides) from sclerotia of Pleurotus tuber-regium (Fries) singer as a potential antitumor agent. J Agric Food Chem. 2001, 49: 5059-5062.PubMed

14.

Ohno N, Furukawa M, Miura NN, Adachi Y, Motoi M, Yadomae T: Antitumor beta glucan from the cultured fruit body of Agaricus blazei. Biol Pharm Bull. 2001, 24: 820-828.PubMed

15.

Takaku T, Kimura Y, Okuda H: Isolation of an antitumor compound from Agaricus blazei Murill and its mechanism of action. J Nutr. 2001, 131: 1409-1413.PubMed

16.

Wang HX, Liu WK, Ng TB, Ooi VE, Chang ST: Immunomodulatory and antitumor activities of a polysaccharide-peptide complex from a mycelial culture of Tricholoma sp., a local edible mushroom. Life Sci. 1995, 57: 269-281.PubMed

17.

Wang H, Gao J, Ng TB: A new lectin with highly potent antihepatoma and antisarcoma activities from the oyster mushroom Pleurotus ostreatus. Biochem Biophys Res Commun. 2000, 275: 810-816.PubMed

18.

Wang HX, Ng TB: Examination of lectins, polysaccharopeptide, polysaccharide, alkaloid, coumarin and trypsin inhibitors for inhibitory activity against human immunodeficiency virus reverse transcriptase and glycohydrolases. Planta Med. 2001, 67: 669-672.PubMed

19.

Mayell M: Maitake extracts and their therapeutic potential. Altern Med Rev. 2001, 6: 48-60.PubMed

20.

Nanba H, Kubo K: Effect of Maitake D-fraction on cancer prevention. Ann N Y Acad Sci. 1997, 833: 204-207.PubMed

21.

Matsui K, Kodama N, Nanba H: Effects of maitake (Grifola frondosa) D-Fraction on the carcinoma angiogenesis. Cancer Lett. 2001, 172: 193-198.PubMed

22.

Finkelstein MP, Aynehchi S, Samadi AA, Drinis S, Choudhury MS, Tazaki H, Konno S: Chemosensitization of carmustine with maitake beta-glucan on androgen-independent prostatic cancer cells: involvement of glyoxalase I. J Altern Complement Med. 2002, 8: 573-580.PubMed

23.

Kawamura Y, Manabe M, Kitta K: Antitumor protein (AP) from a mushroom induced apoptosis to transformed human keratinocyte by controlling the status of prb, c-MYC, cyclin E-cdk2, and p21WAF1 in the G1/S transition. Biofactors. 2000, 12: 157-160.PubMed

24.

Dong Y, Yang MM, Kwan CY: In vitro inhibition of proliferation of HL-60 cells by tetrandrine and coriolus versicolor peptide derived from Chinese medicinal herbs. Life Sci. 1997, 60: PL135-140.PubMed

25.

Ng TB: A review of research on the protein-bound polysaccharide (polysaccharopeptide, PSP) from the mushroom Coriolus versicolor (Basidiomycetes: Polyporaceae). Gen Pharmacol. 1998, 30: 1-4.PubMed

26.

Li XY, Wang JF, Zhu PP, Liu L, Ge JB, Yang SX: Immune enhancement of a polysaccharides peptides isolated from Coriolus versicolor. Zhongguo Yao Li Xue Bao. 1990, 11: 542-545.PubMed

27.

Cui J, Chisti Y: Polysaccharopeptides of Coriolus versicolor: physiological activity, uses, and production. Biotechnol Adv. 2003, 21: 109-122.PubMed

28.

Hsieh TC, Kunicki J, Darzynkiewicz Z, Wu JM: Effects of extracts of Coriolus versicolor (I'm-Yunity) on cell-cycle progression and expression of interleukins-1 beta,-6, and -8 in promyelocytic HL-60 leukemic cells and mitogenically stimulated and nonstimulated human lymphocytes. J Altern Complement Med. 2002, 8: 591-602.PubMed

29.

Zeng F, Hon CC, Sit WH, Chow KY, Hui RK, Law IK, Ng VW, Yang XT, Leung FC, Wan JM: Molecular characterization of Coriolus versicolor PSP-induced apoptosis in human promyelotic leukemic HL-60 cells using cDNA microarray. Int J Oncol. 2005, 27: 513-523.PubMed

30.

Hui KP, Sit WH, Wan JM: Induction of S phase cell arrest and caspase activation by polysaccharide peptide isolated from Coriolus versicolor enhanced the cell cycle dependent activity and apoptotic cell death of doxorubicin and etoposide, but not cytarabine in HL-60 cells. Oncol Rep. 2005, 14: 145-155.PubMed

31.

Yang X, Sit WH, Chan DK, Wan JM: The cell death process of the anticancer agent polysaccharide-peptide (PSP) in human promyelocytic leukemic HL-60 cells. Oncol Rep. 2005, 13: 1201-1210.PubMed

32.

Dipietrantonio A, Hsieh TC, Wu JM: Differential effects of retinoic acid (RA) and N-(4-hydroxyphenyl) retinamide (4-HPR) on cell growth, induction of differentiation, and changes in p34cdc2, Bcl-2, and actin expression in the human promyelocytic HL-60 leukemic cells. Biochem Biophys Res Commun. 1996, 224: 837-842.PubMed

33.

DiPietrantonio AM, Hsieh TC, Olson SC, Wu JM: Regulation of G1/S transition and induction of apoptosis in HL-60 leukemia cells by fenretinide (4HPR). Int J Cancer. 1998, 78: 53-61.PubMed

34.

Hsieh TC, Wu JM: Mechanism of action of herbal supplement PC-SPES: elucidation of effects of individual herbs of PC-SPES on proliferation and prostate specific gene expression in androgen-dependent LNCaP cells. Int J Oncol. 2002, 20: 583-588.PubMed

35.

Hsieh TC, Wang Z, Hamby CV, Wu JM: Inhibition of melanoma cell proliferation by resveratrol is correlated with upregulation of quinone reductase 2 and p53. Biochem Biophys Res Commun. 2005, 334: 223-230.PubMed

36.

Hsieh TC, Wu JM: Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp Cell Res. 1999, 249: 109-115.PubMed

37.

Darzynkiewicz Z, Bedner E, Smolewski P: Flow cytometry in analysis of cell cycle and apoptosis. Semin Hematol. 2001, 38: 179-193.PubMed

38.

Fu Y, Hsieh TC, Guo J, Kunicki J, Lee MY, Darzynkiewicz Z, Wu JM: Licochalcone-A, a novel flavonoid isolated from licorice root (Glycyrrhiza glabra), causes G2 and late-G1 arrests in androgen-independent PC-3 prostate cancer cells. Biochem Biophys Res Commun. 2004, 322: 263-270.PubMed

39.

Hsieh TC, Juan G, Darzynkiewicz Z, Wu JM: Resveratrol increases nitric oxide synthase, induces accumulation of p53 and p21(WAF1/CIP1), and suppresses cultured bovine pulmonary artery endothelial cell proliferation by perturbing progression through S and G2. Cancer Res. 1999, 59: 2596-2601.PubMed

40.

Lu X, Hsieh TC, Wu JM: Equiguard suppresses androgen-dependent LNCaP prostate cancer cell proliferation by targeting cell cycle control via down regulation of the retinoblastoma protein Rb and induction of apoptosis via the release of cytochrome c. Int J Oncol. 2004, 25: 1801-1807.PubMed

41.

Lu X, Guo J, Hsieh TC: PC-SPES inhibits cell proliferation by modulating p21, cyclins D, E and B and multiple cell cycle-related genes in prostate cancer cells. Cell Cycle. 2003, 2: 59-63.PubMed

42.

Hsieh TC, Lu X, Guo J, Xiong W, Kunicki J, Darzynkiewicz Z, Wu JM: Effects of herbal preparation Equiguard on hormone-responsive and hormone-refractory prostate carcinoma cells: mechanistic studies. Int J Oncol. 2002, 20: 681-689.PubMed

43.

Lu X, Guo J, Hsieh TC, Wu JM: Inhibition of proliferation and expression of AR/PSA by herbal supplement Equiguard in LNCaP cells cultured in androgen-proficient FBS and androgen-deficient charcoal-stripped FBS is correlated with increased serine-15 phosphorylation of the tumor suppressor gene p53. Anticancer Res. 2003, 23: 2489-2498.PubMed

44.

Taya Y: RB kinases and RB-binding proteins: new points of view. Trends Biochem Sci. 1997, 22: 14-17.PubMed

45.

Darzynkiewicz Z, Bedner E, Traganos F, Murakami T: Critical aspects in the analysis of apoptosis and necrosis. Hum Cell. 1998, 11: 3-12.PubMed

46.

Wu JM, DiPietrantonio AM, Hsieh TC: Mechanism of fenretinide (4-HPR)-induced cell death. Apoptosis. 2001, 6: 377-388.PubMed

47.

Darzynkiewicz Z, Smolewski P, Bedner E: Use of flow and laser scanning cytometry to study mechanisms regulating cell cycle and controlling cell death. Clin Lab Med. 2001, 21: 857-873.PubMed

48.

Darzynkiewicz Z, Huang X, Okafuji M, King MA: Cytometric methods to detect apoptosis. Methods Cell Biol. 2004, 75: 307-341.PubMed

49.

Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science. 1995, 267: 1456-1462.PubMed

50.

Duckett CS, Thompson CB: The control and execution of programmed cell death: an update. Biochim Biophys Acta. 1997, 1332: R45-47.PubMed

51.

Tsai SY, Ardelt B, Hsieh TC, Darzynkiewicz Z, Shogen K, Wu JM: Treatment of Jurkat acute T-lymphocytic leukemia cells by onconase (Ranpirnase) is accompanied by an altered nucleocytoplasmic distribution and reduced expression of transcription factor NF-kappaB. Int J Oncol. 2004, 25: 1745-1752.PubMed

52.

Perkins ND, Gilmore TD: Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ. 2006, 13: 759-772.PubMed

53.

Campbell KJ, Perkins ND: Regulation of NF-kappaB function. Biochem Soc Symp. 2006, 165-180.

54.

Aggarwal BB: Nuclear factor-kappaB: the enemy within. Cancer Cell. 2004, 6: 203-208.PubMed

55.

Shishodia S, Aggarwal BB: Nuclear factor-kappaB: a friend or a foe in cancer?. Biochem Pharmacol. 2004, 68: 1071-1080.PubMed

56.

Kumar A, Takada Y, Boriek AM, Aggarwal BB: Nuclear factor-kappaB: its role in health and disease. J Mol Med. 2004, 82: 434-448.PubMed

57.

Shishodia S, Aggarwal BB: Nuclear factor-kappaB activation mediates cellular transformation, proliferation, invasion angiogenesis and metastasis of cancer. Cancer Treat Res. 2004, 119: 139-173.PubMed

58.

Horvath CM: The Jak-STAT pathway stimulated by interferon gamma. Sci STKE. 2004, 2004: tr8-PubMed

59.

Qing Y, Stark GR: Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J Biol Chem. 2004, 279: 41679-41685.PubMed

60.

Kerr IM, Costa-Pereira AP, Lillemeier BF, Strobl B: Of JAKs, STATs, blind watchmakers, jeeps and trains. FEBS Lett. 2003, 546: 1-5.PubMed

61.

Sehgal PB, Guo GG, Shah M, Kumar V, Patel K: Cytokine signaling: STATS in plasma membrane rafts. J Biol Chem. 2002, 277: 12067-12074.PubMed

62.

Shah M, Patel K, Fried VA, Sehgal PB: Interactions of STAT3 with caveolin-1 and heat shock protein 90 in plasma membrane raft and cytosolic complexes. Preservation of cytokine signaling during fever. J Biol Chem. 2002, 277: 45662-45669.PubMed

63.

Lee CK, Smith E, Gimeno R, Gertner R, Levy DE: STAT1 affects lymphocyte survival and proliferation partially independent of its role downstream of IFN-gamma. J Immunol. 2000, 164: 1286-1292.PubMed

64.

Doll R, Peto R: The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 1981, 66: 1191-1308.PubMed

65.

Hsing AW, Tsao L, Devesa SS: International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2000, 85: 60-67.PubMed

66.

Hsing AW, Devesa SS: Trends and patterns of prostate cancer: what do they suggest?. Epidemiol Rev. 2001, 23: 3-13.PubMed

67.

Sporn MB, Suh N: Chemoprevention: an essential approach to controlling cancer. Nat Rev Cancer. 2002, 2: 537-543.PubMed

68.

Sporn MB, Newton DL: Chemoprevention of cancer with retinoids. Fed Proc. 1979, 38: 2528-2534.PubMed

69.

Sporn MB, Suh N: Chemoprevention of cancer. Carcinogenesis. 2000, 21: 525-530.PubMed

70.

Milner JA, McDonald SS, Anderson DE, Greenwald P: Molecular targets for nutrients involved with cancer prevention. Nutr Cancer. 2001, 41: 1-16.PubMed

71.

Greenwald P: Cancer prevention clinical trials. J Clin Oncol. 2002, 20: 14S-22S.PubMed

72.

Greenwald P: Cancer chemoprevention. Bmj. 2002, 324: 714-718.PubMedPubMedCentral

73.

Greenwald P: Clinical trials in cancer prevention: current results and perspectives for the future. J Nutr. 2004, 134: 3507S-3512S.PubMed

74.

Greenwald P, Clifford CK, Milner JA: Diet and cancer prevention. Eur J Cancer. 2001, 37: 948-965.PubMed

75.

Greenwald P, McDonald SS, Anderson DE: An evidence-based approach to cancer prevention clinical trials. Eur J Cancer Prev. 2002, 11 (Suppl 2): S43-47.PubMed

76.

Greenwald P, Milner JA, Anderson DE, McDonald SS: Micronutrients in cancer chemoprevention. Cancer Metastasis Rev. 2002, 21: 217-230.PubMed

77.

Hong WK, Sporn MB: Recent advances in chemoprevention of cancer. Science. 1997, 278: 1073-1077.PubMed

78.

Kelloff GJ, Hawk ET, Karp JE, Crowell JA, Boone CW, Steele VE, Lubet RA, Sigman CC: Progress in clinical chemoprevention. Semin Oncol. 1997, 24: 241-252.PubMed

79.

Kelloff GJ, Lieberman R, Steele VE, Boone CW, Lubet RA, Kopelovich L, Malone WA, Crowell JA, Higley HR, Sigman CC: Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer. Urology. 2001, 57: 46-51.PubMed

80.

Perkins ND: NF-kappaB: tumor promoter or suppressor?. Trends Cell Biol. 2004, 14: 64-69.PubMed

81.

Campbell KJ, O'Shea JM, Perkins ND: Differential regulation of NF-kappaB activation and function by topoisomerase II inhibitors. BMC Cancer. 2006, 6: 101-PubMedPubMedCentral

82.

Campbell KJ, Witty JM, Rocha S, Perkins ND: Cisplatin mimics ARF tumor suppressor regulation of RelA (p65) nuclear factor-kappaB transactivation. Cancer Res. 2006, 66: 929-935.PubMed

83.

Gimonet D, Landais E, Bobichon H, Coninx P, Liautaud-Roger F: Induction of apoptosis by bleomycin in p53-null HL-60 leukemia cells. Int J Oncol. 2004, 24: 313-319.PubMed

84.

Shimizu T, Pommier Y: DNA fragmentation induced by protease activation in p53-null human leukemia HL60 cells undergoing apoptosis following treatment with the topoisomerase I inhibitor camptothecin: cell-free system studies. Exp Cell Res. 1996, 226: 292-301.PubMed

85.

El-Mahdy MA, Zhu Q, Wang QE, Wani G, Wani AA: Thymoquinone induces apoptosis through activation of caspase-8 and mitochondrial events in p53-null myeloblastic leukemia HL-60 cells. Int J Cancer. 2005, 117: 409-417.PubMed

86.

Houle MG, Kahn RA, Naccache PH, Bourgoin S: ADP-ribosylation factor translocation correlates with potentiation of GTP gamma S-stimulated phospholipase D activity in membrane fractions of HL-60 cells. J Biol Chem. 1995, 270: 22795-22800.PubMed

87.

Martin A, Brown FD, Hodgkin MN, Bradwell AJ, Cook SJ, Hart M, Wakelam MJ: Activation of phospholipase D and phosphatidylinositol 4-phosphate 5-kinase in HL60 membranes is mediated by endogenous Arf but not Rho. J Biol Chem. 1996, 271: 17397-17403.PubMed

88.

Guillemain I, Exton JH: Effects of brefeldin A on phosphatidylcholine phospholipase D and inositolphospholipid metabolism in HL-60 cells. Eur J Biochem. 1997, 249: 812-819.PubMed

89.

Skippen A, Jones DH, Morgan CP, Li M, Cockcroft S: Mechanism of ADP ribosylation factor-stimulated phosphatidylinositol 4,5-bisphosphate synthesis in HL60 cells. J Biol Chem. 2002, 277: 5823-5831.PubMed

90.

Denk A, Goebeler M, Schmid S, Berberich I, Ritz O, Lindemann D, Ludwig S, Wirth T: Activation of NF-kappa B via the Ikappa B kinase complex is both essential and sufficient for proinflammatory gene expression in primary endothelial cells. J Biol Chem. 2001, 276: 28451-28458.PubMed

91.

Perona R, Montaner S, Saniger L, Sanchez-Perez I, Bravo R, Lacal JC: Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes Dev. 1997, 11: 463-475.PubMed

92.

Nelson WG, De Marzo AM, Isaacs WB: Prostate cancer. N Engl J Med. 2003, 349: 366-381.PubMed

93.

Narayanan BA, Narayanan NK, Pittman B, Reddy BS: Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res. 2004, 10: 7727-7737.PubMed

94.

Narayanan BA, Narayanan NK, Pttman B, Reddy BS: Adenocarcina of the mouse prostate growth inhibition by celecoxib: Downregulation of transcription factors involved in COX-2 inhibition. Prostate. 2005

95.

Kashfi K, Rigas B: Is COX-2 a 'collateral' target in cancer prevention?. Biochem Soc Trans. 2005, 33: 724-727.PubMed

96.

Ranger GS, Thomas V, Jewell A, Mokbel K: Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer. Anticancer Res. 2004, 24: 2349-2351.PubMed

97.

Spano JP, Chouahnia K, Morere JF: [Cyclooxygenase 2 inhibitors and lung carcinoma]. Bull Cancer. 2004, 91 (Suppl 2): S109-112.

98.

Monro JA: Treatment of cancer with mushroom products. Arch Environ Health. 2003, 58: 533-537.PubMed

99.

Wasser SP: Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol. 2002, 60: 258-274.PubMed

100.

Fisher M, Yang LX: Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Res. 2002, 22: 1737-1754.PubMed

101.

Howard KA, Li XW, Somavarapu S, Singh J, Green N, Atuah KN, Ozsoy Y, Seymour LW, Alpar HO: Formulation of a microparticle carrier for oral polyplex-based DNA vaccines. Biochim Biophys Acta. 2004, 1674: 149-157.PubMed

102.

Ross BP, Toth I: Gastrointestinal absorption of heparin by lipidization or coadministration with penetration enhancers. Curr Drug Deliv. 2005, 2: 277-287.PubMed

103.

Kim SK, Lee EH, Vaishali B, Lee S, Lee YK, Kim CY, Moon HT, Byun Y: Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates. J Control Release. 2005, 105: 32-42.PubMed

104.

Kim SK, Vaishali B, Lee E, Lee S, Lee YK, Kumar TS, Moon HT, Byun Y: Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous formulation. Thromb Res. 2005

105.

Bernkop-Schnurch A, Kast CE, Guggi D: Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: thiomer/GSH systems. J Control Release. 2003, 93: 95-103.PubMed

106.

Tsai MF, Chiang YL, Wang LF, Huang GW, Wu PC: Oral sustained delivery of diclofenac sodium using calcium chondroitin sulfate matrix. J Biomater Sci Polym Ed. 2005, 16: 1319-1331.PubMed

107.

Sinha VR, Kumria R: Polysaccharides in colon-specific drug delivery. Int J Pharm. 2001, 224: 19-38.PubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/6/30/prepub

Title: Induction of cell cycle changes and modulation of apoptogenic/anti-apoptotic and extracellular signaling regulatory protein expression by water extracts of I'm-Yunity™ (PSP)
Authors: Tze-chen Hsieh
Peili Wu
Spencer Park
Joseph M Wu
Publication date: 01-12-2006
Publisher: BioMed Central
Published in: BMC Complementary Medicine and Therapies / Issue 1/2006
Electronic ISSN: 2662-7671
DOI: https://doi.org/10.1186/1472-6882-6-30

At a glance: The STEP trials

Springer Medicine

Induction of cell cycle changes and modulation of apoptogenic/anti-apoptotic and extracellular signaling regulatory protein expression by water extracts of I'm-Yunity™ (PSP)

Abstract

Background

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2006

The effect of long term combined yoga practice on the basal metabolic rate of healthy adults

Dietary supplement use among health care professionals enrolled in an online curriculum on herbs and dietary supplements

Catharanthus roseus flower extract has wound-healing activity in Sprague Dawley rats

Effect of three different cultivars of Lepidium meyenii (Maca) on learning and depression in ovariectomized mice

Inhibitory effect of green coffee bean extract on fat accumulation and body weight gain in mice

Development of a taxonomy to describe massage treatments for musculoskeletal pain